Little is known about T-cell immune response of patients to advanced gastrointestinal (GI) adenocarcinomas. How immunotherapy could be a relevant alternative to current therapeutics for these common malignancies is unclear. Conversely, adoptive transfer of tumor-infiltrating lymphocytes (TIL) can mediate durable complete regression of metastatic melanoma in patients with refractory disease. By overcoming the difficulty of establishing new cancer cell lines and by expanding TIL from the same patients, this study first provides evidence at the molecular level 
Translational Relevance
Little is known about T-cell immune response of patients to advanced gastrointestinal (GI) adenocarcinomas. How immunotherapy could be a relevant alternative to current therapeutics for these common malignancies is unclear. Conversely, adoptive transfer of tumor-infiltrating lymphocytes (TIL) can mediate durable complete regression of metastatic melanoma in patients with refractory disease. By overcoming the difficulty of establishing new cancer cell lines and by expanding TIL from the same patients, this study first provides evidence at the molecular level was used to define HLA-restriction elements and specific reactivity.
Results: TIL were expanded from metastases in all patients, and new tumor cell lines generated in five patients. Autologous tumor-recognition without cross-reactivity against allogeneic HLAmatched GI tumors was found in CD8 + TIL from three of these five patients. In a patient with gastric cancer liver metastases, the repertoire of CD8 
Conclusions:
This study provides a basis for the development of immunotherapy for patients with advanced GI malignancies by first establishing the presence of naturally occurring tumorreactive CD8 + TIL at the molecular level.
Introduction
Gastrointestinal (GI) adenocarcinomas are among the ten most common malignancies worldwide and the overall mortality associated with their high metastatic potential has not changed significantly over the last decades (1) . Current multimodality treatments can slow disease progression but fail to cure patients with metastatic disease. Thus far, immune-based therapies have not shown clinical effectiveness in patients with GI cancers (2) (3) (4) (5) . A positive association between the density of the tumor-infiltrating lymphocyte (TIL) infiltrate and better outcomes has nonetheless been reported in patients with adenocarcinomas arising in the esophagus, stomach, pancreas, liver, bile ducts, gallbladder, colon, and rectum (6) . Multiple immune escape mechanisms have however been proposed that may contribute to the absence, the depletion, and the dysfunction of tumor-reactive TIL in solid tumors (7) (8) (9) . Thus the specific recognition of human metastatic GI cancers by naturally occurring, autologous, cytotoxic CD8 + T cells harvested from the tumor site has not been defined at the T-cell clonal level with defined HLA restriction elements.
Results from studies in patients with metastatic melanoma have stimulated us to investigate the anti-tumor reactivity of CD8 + TIL in common epithelial malignancies. Indeed, TIL isolated from melanoma metastases can exhibit direct in vitro tumor recognition of defined antigens presented by specific class I HLAs (10) (11) (12) (13) (14) , and tumor deposits appear to harbor antitumor T cells of sufficient avidity and in sufficient numbers to respond to non-specific systemic modulation of immunity (15) (16) (17) (18) . Additionally, as now reported by multiple institutions, the adoptive cell transfer of autologous TIL can mediate complete cancer regression in patients with metastatic disease considered incurable with standard therapy, with complete responders reported up to 10 years after treatment (19) (20) (21) (22) (23) 
Methods

Patients and tumor processing
Written informed consent was obtained from all patients enrolled under protocols approved by the Institutional Review Board of the National Cancer Institute (NCI) and U.S.
Food and Drug Administration. Single cell suspensions were obtained from freshly resected tumors by independent enzymatic digestion and mechanical dispersion as previously described for melanoma specimens (24).
Primary human cancer cell cultures and culture of other cancer cell lines
To develop cancer cell lines, 0.25e6 live nucleated cells were plated in multiple 25 cm Author Manuscript Published OnlineFirst on November 11, 2013; DOI: 10.1158/1078-0432.CCR- suggested conditions. Human melanoma cell lines 3350 and 624, and human pancreatic cancer cell line 2596 and 2742-2, were established in our laboratory.
The authenticity of all cell lines was confirmed by HLA typing and testing expression of melanoma differentiation antigens (MART-1, Melan-A, gp100) and GI cancer antigens (CEA, pan-cytokeratins). Mycoplasma contamination was ruled out on all cell cultures by using MycoAlert (Lonza) according to the manufacturer instructions.
Generation of TIL
TIL establishment and expansion followed techniques used for metastatic melanoma tumor deposits and are presented in supplementary methods (24, 25) . release 4-6 h cytolysis assays were used as described in previous studies (26, 27) Research. (28) . Consensus regions were determine using the International Immunogenetics Information System (29) for sequence analysis of 96 colonies picked from each 5' RACE product of both TCR alpha and beta chains and their variable regions. Murinized human TCRs were cloned into MSGV1 retroviral vectors as described (30) and detailed in supplementary methods. Transduction of PBMC was done as described (31), and efficiency assessed after one week expansion by flow cytometry using an anti-mouse TCR β- 
Characteristics of fresh TIL and cultured lines
Results
Patient and tumor clinicopathological and immunological characteristics
Resected tumors from sixteen patients with widespread, moderately to poorly differentiated metastatic adenocarcinomas originating from the stomach, the bile duct, or the colon were studied ( Table 1 
TIL expansion from gastrointestinal metastases
Establishment of new gastrointestinal cancer cell lines and MHC-I expression loss
In parallel to setting up cultures for TIL expansion, as many cancer cell lines as possible were generated for each patient by initial culturing of tumor cell suspensions in ultra-low attachment flasks in addition to standard techniques in adherent flasks. When tumor spheroids were obtained, as in patients 3, 5, and 11, multiple cell lines were initiated from distinct spheroids, and thus 13 cancer cell lines were established in five patients (Table 1, Fig. S1 ).
Complete HLA genotyping of the cancer cell lines and PBMC confirmed the parenthood of the lines for each patient (Table S1 ). Loss of heterozygosity at the HLA loci (haplotype loss) was found in two out of the 13 newly established cancer cell lines (patients 9 and 10). Total loss of MHC-I protein expression was seen in addition to genomic HLA haplotype loss in the only one colon cancer cell line generated from patient 10 (CAPM) (Fig. 1 ), rendering this cell line "invisible" for CD8 + T cells.
CD8 + TIL recognition of newly established autologous cancer cell lines
After expansion, CD8 + TIL recognition of autologous GI cancer was evaluated by examining their ability to secrete IFN-γ and to up-regulate expression of the inducible activation marker 4-1BB (CD137) (32) in response to tumor stimulation in the five patients for which new cancer cell lines had been established ( were not reactive to 4 autologous cancer cell lines (CAAWM) ( Table S2) . TIL reactivity to autologous tumors was however detected at different levels in 3 patients with metastatic GI adenocarcinoma originating from 3 different organs: stomach (patient 3), intrahepatic bile ducts (patient 5), and colon (patient 9) ( Table 2 ). percentages of 4-1BB expression upregulation, although low, were reproducible in sequential experiments, increased with prolonged autologous tumor stimulations, and were consistently higher than either the percentage of unstimulated TIL expressing 4-1BB (0.3%), or the percentage of TIL stimulated with allogeneic cancer cell lines, such as GALMa (0.1%) ( Table 2) .
In patient 9, the CD8 + TIL expanded from a colon cancer liver metastasis were highly oligoclonal, as 93% (62 out of 67 sequences) shared the same rearranged 7-9*03 TCR-BV sequence (Fig. S2) . Co-cultures carried out with a low passage of the autologous colon cancer (Table S3 for (Table S3) . We estimated that the frequency of the TRBV9 TCR was of less than 1.3% of CD8 + TIL expanded from the metastasis, since this specific TCR sequence did not match any of the one initially analyzed (n=76) from the bulk CD8 + TIL ( Fig. 2A) . Fig. 2D bar graphs; non-reactivity to allogeneic targets not shown). The two clones did not share the same TCR (TRBV28 and TRBV3-1, see Table S3 ) and were found at a frequency of less than lyse both cell line GALMa and c (Fig. 3A) . For patient 2 similarly, the 4-1BB up-regulation seen by the TRBV28 and TRBV3-1 clones after stimulation by BAOMa and BAAM was associated with cytolysis of tumor lines from patient 5 but not from patient 3. Thus CD8 + TIL clones with specific lytic capacity toward autologous cancer cells were isolated from a metastatic gastric adenocarcinoma and a cholangiocarcinoma.
TCR-transduced lymphocytes redirected to recognize gastric and bile duct cancers restricted to the autologous context by common HLA
We next synthesized the genes encoding the TCRs derived from reactive TIL clones isolated from patients 3 and 5, as well as the dominant TCR found in patient 9 ( bulk CD8+). The TRBV6-1 lymphocyte reactivity was entirely specific to the autologous tumor, despite the fact that the restriction element HLA-C*0701 allele was potentially expressed by 13 other allogeneic tumor targets (Table S1 ). For patient 5, the TRBV28 TCR-transduced PBMC recognized the autologous cell lines established from this patient's omental nodule (BAOMa and b) and malignant ascites (BAAM) (Fig. 4C, middle, lighter green bar) . The reactivity of the TRBV3-1 was weaker but specific to the autologous tumor (Fig. 4C, dark green bar) . Again, Altogether, these results showed that it was possible to redirect PBMC specificity toward GI cancer antigens presented by distinct HLA class I alleles, and that the antigens recognized in the autologous setting were likely unique to each patient. 
tumor CD8 + T-cell recognition (37) . In silico-based epitope prediction analysis has suggested that 2 to 17 HLA-A*0201 mutated epitopes may be generated per colon cancer (38) .
Additionally, even if a productive anti-tumor immune response occurred against mutated epitopes, it is possible that over time, a natural selection of the least immunogenic cancer cells occurs, as suggested in animal models (39, 40) . Here, our ability to establish new cancer cell lines in a limited number of patients with advanced GI cancers consistently supported a low frequency of tumor-reactive CD8+ TIL, but more samples should be tested to further examine this phenomenon. Higher frequencies of GI tumor-reactive TIL may be found in earlier stages of disease, or in GI cancer subsets, such as those with a high mutation rate due to mismatch repair gene deficiencies.
Our study thus demonstrates that tumor-reactive T cells with proliferative potential may be isolated from advanced GI cancer, provided that suitable tumor targets are available for testing. Thus far, CD137 (4-1BB), a cell surface marker of recent TCR engagement, had been used for isolation of precursor T cells derived from PBMC, using peptides from known tumor or viral antigens as stimulators (32, 41, 42) . Without knowing the antigens recognized by polyclonal TIL, the use of 4-1BB expression here allowed to isolate polyclonal cytolytic CD8 + T cells, independent of their capacity to secrete IFN-γ ( Fig. 2 and 3 
By defining the reactivity of CD8 + T cells against GI cancers at the TCR and the HLA molecular level and by testing allogeneic reactivity against a comprehensive panel of HLAgenotyped GI cancer cell lines, our study highlighted an additional difference with melanoma, which is the absence of shared recognition across allogeneic tumors (Table S2, Fig.4) . TIL in melanoma not only recognize mutated epitopes, but many self-epitopes, such as cancer testis antigens (MAGE, NY-ESO1, etc.) and melanocyte-differentiation antigens (gp100, MART-1, etc.) (10) (11) (12) (13) . While ongoing studies are aimed at identifying the genes that encode the antigens recognized by GI TIL, conceivably these may consist of mutation-generated epitopes unique to Although the genetic heterogeneity found in a given tumor and across distinct metastases in a given patient is now well established using second generation genomic sequencing (37, 48, 49) , our data support that this heterogeneity can translate into the generation of various cell lines with the distinct potential of being recognized by autologous CD8 (Fig. 1 and Table 1 ).
Implications of these findings for advanced GI cancer immunotherapy are twofold: First, a nonpolyclonal immunologic approach that only targets one tumor antigen is unlikely to mediate sustained tumor regression. Second, the antigen presentation capacity of cancer cells should be evaluated as a potential biomarker of response to immunotherapy, while strategies that aim at restoring antigen presentation have to be developed to broaden the use of T-cell based immunotherapy.
In conclusion, this study defines at the clonal and molecular level the existence of naturally-occurring cytolytic CD8 + TIL specifically reactive to autologous metastatic GI cancers.
These findings propose avenues for the development of T-cell based immunotherapies for GI cancers by pointing to main challenges to be addressed, such as the low frequency of tumorreactive TIL, the absence of shared antigen recognition across allogeneic tumors, the difficulty in establishing suitable tumor targets for the selection of reactive TIL, the heterogeneity of antigen expression by tumors, and the loss of MHC-I expression by immune-escape tumor variants.
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